Riskpilot← Back to searchSign inGet full accessZinobra Diagnostics AB
ABActiveOrg 5561452011Sjöbacka Fallhagen 1All other professional, scientific and technical activities n.e.c. · NACE 7499Est. 19710 employees
Revenue 2024
SEK 268K
-2% vs 2023
EBITDA margin
53.3%
-9% vs 2023
Equity ratio
12.1%
Financial strength
Net profit 2024
SEK 93K
-13% vs 2023
| Revenue | SEK 268K | -2% |
| EBITDA | SEK 143K | -9% |
| Net profit | SEK 93K | -13% |
| Total assets | SEK 3,9M | +2% |
| Equity | SEK 470K | +25% |
| Employees | 0 | — |
Legal name
Zinobra Diagnostics AB
Org number
5561452011
Legal form
Aktiebolag
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
29 mars 1971
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet är äga och förvalta fastigheter, samt utveckla, tillverka och marknadsföra medicinskt diagnostiska och terapeutiska produkter och därmed förenlig verksamhet.
Address
Sjöbacka Fallhagen 1
Phone
+46736229484
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 324 | 341 | 324 | 274 | 268 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 83 | 195 | 132 | 157 | 143 |
| Depreciation & amort. | −43 | −43 | −43 | −43 | −43 |
| EBIT | 40 | 152 | 89 | 114 | 100 |
| Net financials | −31 | −43 | −66 | −7 | −7 |
| Profit before tax | 8 | 110 | 23 | 107 | 93 |
| Tax | −0 | −0 | — | — | — |
| Net profit | 8 | 110 | 23 | 107 | 93 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 439 | 3 582 | 3 737 | 3 812 | 3 884 |
| Equity | 137 | 247 | 270 | 377 | 470 |
| Long-term debt | 3 150 | 3 274 | 3 316 | 3 382 | 3 389 |
| Short-term debt | 153 | 61 | 151 | 53 | 25 |
| Total debt | 3 303 | 3 335 | 3 467 | 3 435 | 3 414 |
EBITDA margin
53.3%
This company
15.8%
Market median
+237% vs market
20202024
Equity ratio
12.1%
This company
38.2%
Market median
-68% vs market
20202024
Return on equity
19.7%
This company
18.4%
Market median
+7% vs market
20202024
Net profit margin
34.6%
This company
8.1%
Market median
+327% vs market
20202024
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20202024
Debt / equity
7.27×
This company
0.62×
Market median
-1073% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JM Audit | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2025 | |
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2025 | |
| Board of Directors | 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Zinobra Diagnostics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jessica Maria Semb | Audit | 0 companies |
| Mats Gustaf Rånby | Chairman | 0 companies |
| Birgitta Wajntraub | Deputy Board Member | 0 companies |
| Anders Lars Danielsson | Deputy Board Member | 0 companies |
| Xerxes Dag Wilhelm Tarzan Rånby | Board of Directors | 0 companies |